103898-38-0
| 中文名稱 | 103898-38-0 |
|---|---|
| 中文同義詞 | 化合物 T16897;化合物 SM-6586 |
| 英文名稱 | SM 6586 |
| 英文同義詞 | SM 6586;3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-, methyl ester;SM6586,SM 6586 |
| CAS號(hào) | 103898-38-0 |
| 分子式 | C26H27N5O5 |
| 分子量 | 489.52 |
| EINECS號(hào) | |
| 相關(guān)類別 | |
| Mol文件 | 103898-38-0.mol |
| 結(jié)構(gòu)式 |  |
103898-38-0 性質(zhì)
| 熔點(diǎn) | 127-128 °C |
|---|---|
| 沸點(diǎn) | 624.0±65.0 °C(Predicted) |
| 密度 | 1.270±0.06 g/cm3(Predicted) |
| 儲(chǔ)存條件 | Store at -20°C |
| 溶解度 | 溶于二甲基亞砜 |
| 酸度系數(shù)(pKa) | 5.10±0.50(Predicted) |
SM-6586 是一種 calcium channel 的拮抗劑，同時(shí)能夠抑制 Na+/H+ 和 Na+/Ca2+ exchange transport，主要用于研究腦血管疾病和高血壓等疾病。
In SM-6586-treated spontaneously hypertensive rats, the survival rate after bilateral common carotid artery ligation is higher, the brain water content is lower, and the ATP level is higher and lactate level. In focal ischemia models, the SM-treated group shows a reduction of T1 relaxation time. The brain water content is significantly decreased in the SM-treated group.